- Investing.com
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The company was founded in 2001 and is headquartered in Kunming, China.
Metrics to compare | 300142 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300142PeersSector | |
|---|---|---|---|---|
P/E Ratio | 402.1x | 42.2x | −0.6x | |
PEG Ratio | −6.73 | −0.67 | 0.00 | |
Price/Book | 2.0x | 2.3x | 2.6x | |
Price / LTM Sales | 8.3x | 6.7x | 3.3x | |
Upside (Analyst Target) | −43.5% | 24.1% | 41.2% | |
Fair Value Upside | Unlock | 2.2% | 4.8% | Unlock |